Luteinizing hormone–releasing hormone (LH–RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors-Reference-Cited by-同舟云学术

Luteinizing hormone–releasing hormone (LH–RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

Published:1998-10 Issue:1-3 Volume:77 Page:185-192
ISSN:0167-0115
Container-title:Regulatory Peptides
language:en
Short-container-title:Regulatory Peptides

Author:

Lamharzi Najib,Schally Andrew V,Koppán Miklós

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Clinical Biochemistry,Endocrinology,Physiology,Biochemistry

Reference44 articles.

1. Cancer statistics;Parker;CA Cancer J Clin,1996

2. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, editors. Cancer Medicine. Baltimore, Williams and Wilkins publishers, 4th edition, 1997:1067–85.

3. Present status of agonistic and antagonistic analogs of LH–RH in the treatment of advanced prostate cancer;Schally;Biomed Pharmacother,1990

4. Somatostatin receptors in human prostate and prostate cancer;Reubi;J Clin Endocrinol Metab,1995

5. Insulin-like growth factor I (IGF-1) receptors, IGF-1 and IGF-2 are expressed in primary human sarcomas;Sekyi-Otu;Cancer Res,1995

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions;International Journal of Molecular Sciences;2020-12-14

2. Discovery of LHRH and development of LHRH analogs for prostate cancer treatment;The Prostate;2017-04-27

3. Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27);Therapeutic Advances in Urology;2015-03-04

4. Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer;Recent Patents on Anti-Cancer Drug Discovery;2014-07-23

5. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies;Cancer Treatment Reviews;2013-10